Results 1 to 10 of about 25,220 (171)

Exploring Ebola virus-associated gene expression through comparative analysis [PDF]

Frontiers in Genetics
IntroductionEbola virus (EBOV) infection triggers intense host transcriptional responses that overlap extensively with those induced by other viral and bacterial pathogens.
Mostafa Rezapour, Sean V. Murphy, David A. Ornelles, Thomas D. Shupe, Stephen J. Walker, Alan R. Jacobson, Metin Nafi Gurcan, Patrick M. McNutt, Anthony Atala   +8 more
doaj   +2 more sources

Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge

EBioMedicine, 2019
Summary: Background: Ebola virus (EBOV), variant Makona, was the causative agent of the 2013–2016 West African epidemic responsible for almost 30,000 human infections and over 11,000 fatalities.
Heinz Feldmann, Friederike Feldmann, Elaine Haddock   +2 more
exaly   +3 more sources

Characterization of the therapeutic effect of antibodies targeting the Ebola glycoprotein using a novel BSL2-compliant rVSVΔG-EBOV-GP infection model

Emerging Microbes and Infections, 2021
Ebola virus (EBOV) infections cause haemorrhagic fever, multi-organ failure and death, and survivors can experience neurological sequelae. Licensing of monoclonal antibodies targeting EBOV glycoprotein (EBOV-GP) improved its prognosis, however, this ...
Ha-Na Lee, Derek D C Ireland, Aaron Lewkowicz   +2 more
exaly   +3 more sources

Acute malaria dysregulates specialized lymph node macrophages to suppress vaccine-elicited protection against the Ebola virus [PDF]

mBio
The filovirus, Ebola virus (EBOV), causes outbreaks of EBOV disease (EVD) throughout equatorial Africa. ERVEBO is a replication-competent recombinant vesicular stomatitis virus-vectored vaccine encoding the EBOV glycoprotein (recombinant vesicular ...
Jonah Elliff, Lindsey Grady, Kyle L. O'Donnell, Caitlin Messingham, Kai J. Rogers, Jobaida Akther, Andrew Thurman, Rahul Vijay, Alejandro Pezzulo, Troy Randall, Andrea Marzi, Noah S. Butler, Wendy Maury   +12 more
doaj   +2 more sources

An mRNA vaccine encoding the Ebola virus glycoprotein induces high neutralizing antibody titers and provides strong protection against lethal infections in mouse models [PDF]

Frontiers in Immunology
Ebola virus (EBOV) is the causative agent of Ebola disease (EBOD), a viral hemorrhagic fever with a notably high case fatality rate. Current treatments for EBOD are limited to monoclonal antibodies or two licensed viral vector vaccines, a recombinant ...
Zachary R. Stromberg, Elvia E. Silva, Sara C. Johnston, Dylan M. Johnson, Dominique Hall, Emmanuel F. Adjei, Emmanuel F. Adjei, John A. Altin, Abisola Abisoye-Ogunniyan, Travis Gollott, Wei He, Iris K. A. Jones, Steve Kwilas, Sean J. Lund, Heather L. Mead, Georgia A. Nelson, Lisa Ouyang, Sandra K. G. Peters, Jennifer L. Schwedler, Caleb Z. Trecazzi, Matthew W. Turner, Chunyan Ye, Steven B. Bradfute, Nicholas O. Fischer, Jay W. Hooper, Jason T. Ladner, Jason T. Ladner, Amy Rasley, Amy Rasley, Oscar A. Negrete   +29 more
doaj   +2 more sources

To B or Not to B: Mechanisms of Protection Conferred by rVSV-EBOV-GP and the Roles of Innate and Adaptive Immunity

Microorganisms, 2020
Zaire Ebola virus (EBOV) is a member of the Filoviridae family of negative sense, single-stranded RNA viruses. EBOV infection causes Ebola virus disease (EVD), characterized by coagulopathy, lymphopenia, and multi-organ failure, which can culminate in ...
Ilhem Messaoudi, Amanda N Pinski, Messaoudi Ilhem   +2 more
exaly   +3 more sources

Transcriptional Analysis of Infection With Early or Late Isolates From the 2013–2016 West Africa Ebola Virus Epidemic Does Not Suggest Attenuated Pathogenicity as a Result of Genetic Variation

Frontiers in Microbiology, 2021
The 2013–2016 West Africa Ebola virus (EBOV) epidemic caused by the EBOV-Makona isolate is the largest and longest recorded to date. It incurred over 28,000 infections and ∼11,000 deaths.
Kevin J. Maroney, Amanda N. Pinski, Andrea Marzi, Ilhem Messaoudi, Ilhem Messaoudi, Ilhem Messaoudi   +5 more
doaj   +1 more source

Ebola-Detect: A differential serodiagnostic assay for Ebola virus infections and surveillance in the presence of vaccine-induced antibodies

EBioMedicine, 2022
Summary: Background: Ebola virus (EBOV) vaccines containing glycoprotein (GP) provide protection against severe Ebola virus disease (EVD). EBO vaccinations elicit antibodies that are detectable in Ebola serodiagnostic tests, as EBOV GP is a major target
Supriya Ravichandran, Surender Khurana
doaj   +1 more source

The Ebola Interferon Inhibiting Domains Attenuate and Dysregulate Cell-Mediated Immune Responses. [PDF]

PLoS Pathogens, 2016
Ebola virus (EBOV) infections are characterized by deficient T-lymphocyte responses, T-lymphocyte apoptosis and lymphopenia. We previously showed that disabling of interferon-inhibiting domains (IIDs) in the VP24 and VP35 proteins effectively unblocks ...
Ndongala Michel Lubaki, Patrick Younan, Rodrigo I Santos, Michelle Meyer, Mathieu Iampietro, Mathieu Iampietro, Richard A Koup, Alexander Bukreyev   +7 more
doaj   +1 more source

The Methanolic Extract of Perilla frutescens Robustly Restricts Ebola Virus Glycoprotein-Mediated Entry

Viruses, 2021
Ebola virus (EBOV), one of the most infectious human viruses and a leading cause of viral hemorrhagic fever, imposes a potential public health threat with several recent outbreaks.
Yu-Ting Kuo, Ching-Hsuan Liu, Angela Corona, Elisa Fanunza, Enzo Tramontano, Liang-Tzung Lin   +5 more
doaj   +1 more source